Pci Biotech Holding Asa · LSE:0JGL
Pci Biotech Holding Asa — H1 2024 Earnings Presentation
13 slides from Pci Biotech Holding Asa's earnings presentation, Aug 28, 2024
Slide 1: PCI Biotech - First half-year 2024 Interim Report
PCI Biotech - First half-year 2024 Interim Report Presentation August 28, 2024 Ronny Skuggedal, CEO / CFO Morten Luhr, BD Manager www.pcibiotech.com 1
Slide 2: Important notice and disclaimer
PCI Biotech Important notice and disclaimer This presentation may contain certain forward-looking Factors that could cause these differences include, but are not limited to, statements and forecasts based on uncertainty, since they implementation of PCI Biotech’s strategy and its ability to further
Slide 3: Table of Contents
Table of Contents Operational review - highlights Key financials Outlook Q&A www.pcibiotech.com 3
Slide 4: Gene therapy - advanced medicinal products with groundbreaking potential
1H 2024 GENE THERAPY – ADVANCED MEDICINAL PRODUCTS WITH GROUNDBREAKING POTENTIAL Bioprocessing IN VIVO GENE THERAPY EX VIVO GENE THERAPY Genetic disorders are caused by DNA mutations that may lead to severe disease Gene therapies are potentially life-saving treatments for genetic disorders in a
Slide 5: Viral vector manufacturing - utilising cells as gene therapy factories
1H 2024 VIRAL VECTOR MANUFACTURING - UTILISING CELLS AS “GENE THERAPY FACTORIES” Viral vectors Bioprocessing Producer cell Upstream yield Net yield Purified viral vector Manufacturing challenges for viral vectors include host-cell impurities (e.g. DNA and protein) and low viral vector yield from cel
Slide 6: Photochemical lysis (PCL) - next generation viral vector extraction
1H 2024 PHOTOCHEMICAL LYSIS (PCL) - NEXT GENERATION VIRAL VECTOR EXTRACTION Bioprocessing PCI Biotech develops a novel technology - photochemical lysis (PCL) - to address technical needs in viral vector manufacturing Photochemical lysis selectively releases viral vectors from producer cells with red
Slide 7: Photochemical lysis (PCL) - next generation viral vector extraction
1H 2024 PHOTOCHEMICAL LYSIS (PCL) - NEXT GENERATION VIRAL VECTOR EXTRACTION Bioprocessing Host-cell impurities Producer cell Viral vectors (e.g. AAV) Viral vector extraction Mode of action Net viral vector yield Host-cell impurities Industry standard Non-selective Moderate High Photochemical lysis p
Slide 8: R&D milestones
1H 2024 R&D MILESTONES Bioprocessing Received encouraging feedback from the international search report on the PCL patent application Alpha testing with undisclosed partner was completed with positive feedback, supporting further development of the PCL technology with an emphasis on AAV gene therapy
Slide 9: The path from feasibility tests to commercial manufacturing
1H 2024 THE PATH FROM FEASIBILITY TESTS TO COMMERCIAL MANUFACTURING Feasibility Prototype Commercial Bioprocessing Plate Shake-flask Mini benchtop bioreactor Benchtop bioreactor Bioreactor (0.5-1 mL) (20 mL) (250 mL) (1-10 L) (50-500 L) 2022 2023 2024 Partner-dependent Partner-dependent Proof of con
Slide 10: Key financials, Outlook, Q&A
Key financials Outlook Q&A 10
Slide 11: Finance - 1H 2024 key financial figures
Finance 1H 2024 Key financial figures Cash position estimated to support operations into 2H 2025 Cash position per end June 2024 at NOK 30 million Net change in cash of NOK -15 million in last twelve months and for calendar year 2023 New public grant for 2024, up to NOK 3.5 m by Innovation N
Slide 12: Outlook - Advancing manufacturing of gene therapies
Outlook Advancing manufacturing of gene therapies Bioprocessing 2024 Goals • Complete early-stage field testing • Demonstrate technology in commercially representative model • Ready for late-stage field testing in 2025 Pipeline PCL Programme Feasibility Prototype Commercial Viral vector manufacturin
Slide 13: PCI Biotech - For enquiries
PCI Biotech PCI Biotech For enquiries: Ronny Skuggedal, CEO / CFO Mobile phone: +47 940 05 757 E-mail: rs@pcibiotech.com www.pcibiotech.com 13